U.S. Government Organizations Release Positive Information About VIVITROL (CEPH) for the Treatment of Alcoholism
More News related to ALKS
- Alkermes' Corporate Presentation to be Webcast at the Lazard Capital Markets Healthcare Conference
- After-Hours Movers 11/05: JSDA, ENOC, SAM, RST, ASEI, KFN Higher; MOVE, FNM, CROX, BEBE, BID Lower
- Alkermes (ALKS) Posts Q2 EPS of 1c, Tops by 10c; Guides FY09 Sales
- Alkermes Reports Second Quarter Fiscal 2010 Financial Results
- Alkermes' Corporate Presentation to be Webcast at the Credit Suisse Healthcare Conference
More News related to CEPH
- Pivotal Data Published in the Journal Cancer Demonstrate that TREANDA Induced Durable Responses in Relapsed Indolent Non-Hodgkin's Lymphoma
- Cephalon, Inc. to Webcast R&D Day
- Mayo Clinic Proceedings Publishes Study of NUVIGIL in Patients with Shift Work Disorder
- Trading Review for Jazz Pharmaceuticals Inc. Issued by Beacon Equity
- Soleil Securities Reiterates a 'Buy' on Cephalon (CEPH)
More News related to Corporate News
- Kinross Gold (KGC) Receives Authorization to Re-Commence Exploration on Project in Ecuador
- Sanofi-aventis (SNY) and Regeneron Pharmaceuticals (REGN) to Expand Global Collaboration
- Stryker (SYK) Announces Two Acquisitions
- Adobe (ADBE) Cutting 680 Full-Time Jobs to Align Costs with '10 Operating Plan
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
The Substance Abuse and Mental Health Services Administration (SAMHSA), a public health agency within the U.S. Department of Health and Human Services, issued its quarterly Substance Abuse Treatment Advisory developed for the education of healthcare professionals in the field of substance abuse. The advisory features a comprehensive overview of VIVITROL® (naltrexone for extended- release injectable suspension), the first and only once-monthly injectable medication for the treatment of alcohol dependence, which was approved by the FDA in April 2006.
This advisory follows the publication of an updated version of Helping Patients Who Drink Too Much: A Clinician's Guide from the National Institute on Alcohol Abuse and Alcoholism (NIAAA). The Guide was recently updated to include information about VIVITROL as the most recently FDA-approved medication for the treatment of alcohol dependence.
"We are pleased that these government organizations have formally recognized VIVITROL, the first and only once-monthly injectable medication for the treatment of alcohol dependence, as an important and effective treatment option in their recent publications," said David Gastfriend, MD, Vice President, Medical Affairs at Alkermes (Nasdaq: ALKS). "We encourage healthcare providers, including addiction specialists and primary care doctors, to utilize this valuable information as they evaluate and treat their patients who struggle with the deadly disease of alcoholism."
VIVITROL® is a registered trademark of Cephalon, Inc (Nasdaq: CEPH), Medisorb is a registered trademark of Alkermes, Inc. (Nasdaq: ALKS)
Related Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
